TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Diagnostic accuracy of in-vivo polyp assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severe Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Change in Resting Blood Pressure or Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Change in Laboratory Tests Considered Clinically Significant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Acute Rejection Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Graft Survival
Endpoint domain: Mortality/survival
Primary endpoint: Participant Survival
Endpoint domain: Mortality/survival
Primary endpoint: Blunted central satiety response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Backus Lab Stereoacuity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in contrast sensitivity function of amblyopic eye, fellow eye, and both eyes together
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in acuity as measured using M&S Technologies automated ETDRS acuity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postural perception of the gravitational vertical
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Change in minutes of moderate physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Density Lipoprotein Cholesterol (LDL-Cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: F-18 FDG Tumor Uptake (SUV Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: aspartate aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: plasma triglyceride levels (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gamma-glutamyltransferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: alkaline phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Eyeball Transverse Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spontaneous Preterm Birth
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Solicited Local Adverse Events (AEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Solicited Systemic Adverse Events (AEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Score on NICHQ Vanderbilt assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin reaction to the patch test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire Revised
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Brief Pain Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Improvement assessed by the patient (PGI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: liver function in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity of Ajuvia for supine position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Ajuvia for supine position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supine Sleep Time - Control
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Ki absorption coefficient values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Total Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Herniation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pad-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: red blood cell folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent of Oxygen Saturation Measurements <85%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Categorized as Responders (Cure and Improved) to Zyvox (Linezolid) Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microcirculation of the caput humeri
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in MUC1 Specific Systemic T-Cells Immune Response at Day 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in MUC1 Specific Systemic T-Cells Immune Response at Day 190
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biochemical Response Rate Based on PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patients' participation in symptom management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Office Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unplanned cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Left Atrial Effective Refractory Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hollowness severity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage difference in Annexin A5 targeting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensive Complication Index (CCI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported abstinence from opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection use in sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patient Response to Questionnaire (Spiritual assessments)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in peak isokinetic power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in single fiber specific power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in myosin attachment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Intra-Operative and Post-Operative Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pharmacokinetic outcomes
Primary endpoint: Serum Total Protein and Albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 12-week SBM Frequency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 6/12 Weeks APS Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Confirmed Lymph Nodes Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Student-teacher relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Teacher well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Classroom Assessment Scoring System (CLASS) - Instructional Support dimension
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Faecal bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paretic Risk Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Extremity Functional Scale (LEFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Zarit Burden Interview (short form)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Maximum concentration (Cmax) of DS-3201
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum concentration (Tmax) of DS-3201
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Parasiticidal Concentration (MPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of success (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated blood loss (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Events (MAE) during the first 60 days
Endpoint domain: Adverse events/effects
Primary endpoint: Tridimensional radiographic correction of scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAD-7 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Whiteley 8 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress fracture probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of clusters found
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of completing the Functional Geriatric Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Operating room performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual analogue scale of neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantitative improvements using the Clinician Administered PTSD Scale (CAPS - 5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: compliance of patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety and tolerability of SRT2379
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of SRT2379
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With HBsAg Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduced pain medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With a Vaccine Response for Anti-pertussis Toxoid, Anti-pertactin and Anti-filamentous Haemagglutinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dezocine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UHDRS-TMS difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Confirmed Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: hr-HPV DNA negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 antibody presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SAE incidences
Endpoint domain: Adverse events/effects
Primary endpoint: SUSAR incidences
Endpoint domain: Adverse events/effects
Primary endpoint: TEAE incidences
Endpoint domain: Adverse events/effects
Primary endpoint: Mean PUCAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall diagnostic yield for peripheral pulmonary nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Attitudes Towards Obese Persons (ATOP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Beliefs About Obese Persons (BAOP)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Self-Reported Comfort Level (Pre- and Post- Assessment Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-assessment from patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of asymptomatic Leishmania infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence rate of asymptomatic Leishmania infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence rate of active VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diastolic efficiency index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastric Emptying Half-Time of Solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satiation Expressed as Volume to Fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fasting Gastric Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects With Plasmodium Falciparum Parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Eletriptan area under the concentration time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eletriptan peak concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye gaze response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from new-onset major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of patients achieving major molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in AUCs for multimodal imaging and scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mMASI (modified melasma area and severity index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: proportion of confirmed responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brain NAD+/NADH Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiological treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unmedicated IOP ≤ 19 mmHg at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gas usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Treatment Related Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Right ventricular ejection fraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid Plaque presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EASI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall response rate (Complete Response+Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of intra liver and pancreatic triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fibrosis and inflammation analyses of the adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of lonafarnib
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Tolerability of regimen
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Capillary blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Consistent use of condoms during sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of partners testing for HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Newly tested HIV-infected partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of partners linking to HIV care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immunoglobulin M and immunoglobulin G titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Medical Research Council Dyspnea Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: first impression scale of service facility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: service-learning experience of scale for caring
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: behavioral intention of caring
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Complete Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Actual difference of pain scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients diagnosed with endolymphatic hydrops by electrocochleography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients diagnosed with endolymphatic hydrops by (Dephasing) of acoustic distortion products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients diagnosed with endolymphatic hydrops by 3T MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary Vascular Resistance (PVR) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AMH (anti-mullerian hormone) blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of life on the Dyadic Adjustment Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acute Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Distance Exotropia Control Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensibility for endometriosis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for endometriosis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with tooth color
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in social cognition measures
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Structural and functional brain changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Awareness of patients about colorectal cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Non-progressive Disease at 4 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities Scale for Kids - Performance (ASK-P)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning